Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1342 - Survey for patterns of G-CSF use among cancer patients receiving chemotherapy in Asia


20 Dec 2015


Poster presentation 2


Divya Mishra


Annals of Oncology (2015) 26 (suppl_9): 111-124. 10.1093/annonc/mdv531


D. Mishra1, L. Wang2, A. Ho3, S. H4

Author affiliations

  • 1 Asia Medical Sciences Group, Quintiles, 110003 - New Delhi/IN
  • 2 Asia Medical Sciences Group, Quintiles, Beijing/CN
  • 3 Patient And Site Services, Quintiles, Singapore/SG
  • 4 Biostatistician, Quintiles, Bangalore/IN


Abstract 1342


Several cancer trials and reviews have highlighted the higher incidence of hematologic toxicity in the Asian patients. The use of G-CSF for prophylactic and therapeutic purposes in managing febrile neutropenia varies widely in clinical practice.

In the absence of any existing guidelines specific for Asian patients and attempting to estimate the treating oncologist's preferences and decision points in managing neutropenia with the use of G-CSF in their routine practice, we designed this survey.


The survey was done with treating Oncologists across 10 Asian countries through click tools. For this submission related data, we had kept the survey open between 3rd to 18th August, 2015. This survey is ongoing till 15th of September. The final outputs would be descriptively analysed and applicable statistical tests would be performed.


Total effective responders are 54. In guiding practice, 51% follow NCCN, 22.4% follow ASCO. 66% of physicians think dose intensity of chemo is important for chemo-sensitive tumors patients' survival/efficacy regardless curative or palliative intent, the rests think it important for all of tumor types. During dose dense chemotherapy, majority (89%) prefer G-CSF usage to manage FN rather than hold or reduce chemotherapy dose. In patients with afebrile neutropenia, whatever tumor types, most of doctors would prefer keeping same dose of chemotherapy while using G-CSF for secondary prophylaxis. All physicians consider more than 1 factors to determine the need of primary prophylaxis for patients at risk of FN, and the below factors are most relevant: Aged > 65 (76%), poor performance status (72.2%), cytopenia due to bone marrow involvement (70.4%), active or increased risk of infections (55.6%), poor nutritional status (48.1%) et all. For filgrastim course treatment, majority (73.6%) would use ANC 1000-4999 cells/l as stopping criteria. Convenience and cost are two main factors for doctors to decide selecting Peg filgrastim over filgrastim.


There is marked variability in practice patterns across Asia and an important unmet medical need to define prophylaxis and patient selection criteria in the Asian context is emerging. Full results will be presented at the meeting

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings